share_log

Allarity Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Allarity Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Allarity Therapeutics | PRE 14A：并购重组委托声明
美股SEC公告 ·  06/21 16:47

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. announced a series of amendments to its Certificate of Incorporation, which were approved during the Annual Meeting of Stockholders held on July 26, 2024. The amendments include a reduction in the number of authorized shares from 750,500,000 to 250,500,000 and a decrease in common stock from 750,000,000 to 250,000,000. Additionally, provisions were made to allow for the exculpation of certain officers in specific circumstances, as permitted by law. The amendments are part of a strategic effort to streamline the company's share structure and align with corporate governance practices. The changes were approved by the affirmative vote of the majority of the outstanding shares of the company's common stock entitled to vote. The board of directors had previously adopted resolutions declaring the amendments advisable and in the best interests of the company and its stockholders. The amendments are expected to provide the company with the flexibility to issue shares as needed for general corporate purposes and to potentially reduce future litigation costs associated with frivolous lawsuits.
Allarity Therapeutics, Inc. announced a series of amendments to its Certificate of Incorporation, which were approved during the Annual Meeting of Stockholders held on July 26, 2024. The amendments include a reduction in the number of authorized shares from 750,500,000 to 250,500,000 and a decrease in common stock from 750,000,000 to 250,000,000. Additionally, provisions were made to allow for the exculpation of certain officers in specific circumstances, as permitted by law. The amendments are part of a strategic effort to streamline the company's share structure and align with corporate governance practices. The changes were approved by the affirmative vote of the majority of the outstanding shares of the company's common stock entitled to vote. The board of directors had previously adopted resolutions declaring the amendments advisable and in the best interests of the company and its stockholders. The amendments are expected to provide the company with the flexibility to issue shares as needed for general corporate purposes and to potentially reduce future litigation costs associated with frivolous lawsuits.
Allarity Therapeutics, Inc.宣布一系列修改其章程的修正案并在2024年7月26日年股东大会上获得批准。修改包括将授权股份的数量从7.5亿股减少到2.5亿股，普通股由7.5亿股减少到2.5亿股。此外，还有规定允许在特定情况下免除某些官员的责任，符合法律规定。修改是公司努力简化股份结构、与公司治理实践相一致的一部分。修正案获得了公司普通股的优秀股份的肯定投票。董事会之前已经通过决议宣布对修正案的建议和公司股东最大利益。这些修改预计将为公司提供按照一般企业目的需要发行股份的灵活性，并有可能减少与无聊官司相关的将来的诉讼费用。
Allarity Therapeutics, Inc.宣布一系列修改其章程的修正案并在2024年7月26日年股东大会上获得批准。修改包括将授权股份的数量从7.5亿股减少到2.5亿股，普通股由7.5亿股减少到2.5亿股。此外，还有规定允许在特定情况下免除某些官员的责任，符合法律规定。修改是公司努力简化股份结构、与公司治理实践相一致的一部分。修正案获得了公司普通股的优秀股份的肯定投票。董事会之前已经通过决议宣布对修正案的建议和公司股东最大利益。这些修改预计将为公司提供按照一般企业目的需要发行股份的灵活性，并有可能减少与无聊官司相关的将来的诉讼费用。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间